Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease caused by the loss of motor neurons, and development of effective medicines is urgently required. Induced pluripotent stem cell (iPSC)-based drug repurposing identified the Src/c-Abl inhibitor bosutinib, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Imamura, Keiko, Izumi, Yuishin, Nagai, Makiko, Nishiyama, Kazutoshi, Watanabe, Yasuhiro, Hanajima, Ritsuko, Egawa, Naohiro, Ayaki, Takashi, Oki, Ryosuke, Fujita, Koji, Uozumi, Ryuji, Morinaga, Akiko, Hirohashi, Tomoko, Fujii, Yosuke, Yamamoto, Takuya, Tatebe, Harutsugu, Tokuda, Takahiko, Takahashi, Naoto, Morita, Satoshi, Takahashi, Ryosuke, Inoue, Haruhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716331/
https://www.ncbi.nlm.nih.gov/pubmed/36467452
http://dx.doi.org/10.1016/j.eclinm.2022.101707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716331/
https://www.ncbi.nlm.nih.gov/pubmed/36467452
http://dx.doi.org/10.1016/j.eclinm.2022.101707

Ejemplares similares